ABBV - AbbVie Inc.
| Previous Close | 91.36 |
| Open | 90.96 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 90.52 - 92.28 |
| 52 Week Range | 64.61 - 125.86 |
| Volume | 5,487,837 |
| Avg. Volume | 7,717,953 |
| Market Cap | 145.769B |
| Beta | 1.64 |
| PE Ratio (TTM) | 27.84 |
| EPS (TTM) | 3.30 |
| Earnings Date | Apr 26, 2018 |
| Forward Dividend & Yield | 3.84 (4.20%) |
| Ex-Dividend Date | 2018-04-12 |
| 1y Target Est | 119.52 |
- Zacks•16 hours ago
Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX
Four pharma/biotech companies are set to release earnings report on Apr 26. Let's take a look into how the companies are placed ahead of the upcoming results.
- PR Newswire•18 hours ago
AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
- In clinical studies, more than half of patients receiving risankizumab achieved complete skin clearance (PASI 100) at one year (52 weeks) (1) - The Biologics License Application is supported by four ...
- Market Realist•18 hours ago
A Look at Biogen’s Performance in 1Q18
In 1Q18, Biogen (BIIB) generated revenues of $3.1 billion compared to $2.8 billion in 1Q17. That was an ~11% growth on a year-over-year (or YoY) basis and a ~5% decline on a quarter-over-quarter basis.
- PR Newswire•18 hours ago
AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients
- In SELECT-SUNRISE, upadacitinib met the primary endpoint of ACR20 across all doses (7.5 mg, 15 mg, 30 mg, once-daily) at week 12, with a significant difference in ACR20 compared to placebo observed as ...
- Market Realist•19 hours ago
Why Incyte Stock Fell ~9% on April 24
On April 24, Incyte (INCY) saw a steep decline in its stock price. It registered a decline of ~5% during pre-market trading. The stock price decline was triggered by the news regarding Incyte-Eli Lily (LLY) drug Baricitinib, which is under FDA (U.S. Food and Drug Administration) review.
Market Realist•19 hours agoGilead Sciences’ Inflammation Research Is Seeing Rapid Progress
Gilead Sciences (GILD) is currently studying an investigational therapy, filgotinib, in five Phase 3 trials as a treatment option for RA (rheumatoid arthritis), ulcerative colitis, and Crohn’s disease. The company is studying this therapy for RA in its FINCH 1, 2, and 3 trials. While the FINCH 2 study has completed enrolment, FINCH 1 and FINCH 3 are expected to complete enrolment in 2Q18 and 3Q18, respectively.
- Reuters•yesterday
Supreme Court upholds legality of patent review process
The U.S. Supreme Court on Tuesday gave its stamp of approval to a government review process prized by high technology companies as an easy and cheap way to combat "patent trolls" and others that bring patent infringement lawsuits. The justices ruled 7-2 that a type of in-house patent review at the U.S. Patent and Trademark Office does not violate a defendant's right under the U.S. Constitution to have a case adjudicated by a federal court and jury. The court ruled against Oil States International Inc (OIS.N), a Houston-based oilfield services company that had challenged the legality of the process, called inter partes review (IPR).
- Market Realist•yesterday
Gilead Sciences Focuses on Its Liver Disease Portfolio
By mid-2018, Gilead Sciences (GILD) expects its share of the HCV (hepatitis C) market, where it competes with AbbVie (ABBV), Merck (MRK), and Bristol-Myers Squibb (BMY), to stabilize. This stabilization is anticipated despite rapidly declining drug prices and reducing treatment duration due to new and better therapies. While the company is not expecting any disruptive product launches in the HCV segment in the next few years, it expects gradually declining patient numbers to affect revenue. Liver disease research programs
- Zacks•2 days ago
Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?
Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q1.
- Zacks•2 days ago
Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down
Biogen's (BIIB) earnings beat estimates but sales miss the same marginally in Q1. The company's latest key drug Spinraza's tepid sales compares with its sequential tally.
- Investopedia•2 days ago
How Does Biogen Make its Money?
Biogen is a healthy biotechnology company producing a stream of illness-fighting drugs. Its big sellers treat MS, and it is diversifying its product line.
- Reuters•2 days ago
U.S. Supreme Court upholds legality of patent review process
The U.S. Supreme Court on Tuesday gave its stamp of approval to a government review process prized by high technology companies as an easy and cheap way to combat "patent trolls" and others that bring patent infringement lawsuits. The justices ruled 7-2 that a type of in-house patent review at the U.S. Patent and Trademark Office does not violate a defendant's right under the U.S. Constitution to have a case adjudicated by a federal court and jury. The court ruled against Oil States International Inc, a Houston-based oilfield services company that had challenged the legality of the process, called inter partes review (IPR).
- Motley Fool•2 days ago
This Small Biotech Is Building on a Surprising Success
Enanta Pharmaceuticals helped AbbVie score big last year. Now it's setting its sights even higher.
- Motley Fool•2 days ago
Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma
It's a lot easier to be patient once those quarterly payments start adding up.
- Reuters•2 days ago
Amid drug price worries, earnings to test U.S. pharma, biotech shares
Major U.S. pharmaceutical and biotechnology companies, whose shares have been laggards even in a sluggish market, face a litmus test in the corporate earnings season as investors already gun-shy over concerns about pressures on drug prices prepare to give a sharp eye for both hits and misses. As a group, pharmaceutical stocks in the S&P 500 are down about 4 percent so far this year, while S&P biotech stocks are off about 6 percent. Shares of Biogen Inc, Celgene Corp and Bristol-Myers Squibb Co are all down at least 14 percent this year.
- Market Realist•2 days ago
Johnson & Johnson’s Revenues Continued to Rise in 1Q18
Johnson & Johnson (JNJ) reported 12.6% growth in its revenues to $20.0 billion during 1Q18 as compared to revenues of $17.8 billion during 1Q17. The company surpassed Wall Street analyst estimates for EPS (earnings per share) and revenues and reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q17.
- Zacks•3 days ago
Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy
Let's dig into the earnings picture of the companies that would drive the performance of the popular health care ETFs in the coming days.
- Simply Wall St.•6 days ago
AbbVie And Other Great Pharma And Biotech Income Stocks
Pharmaceutical and biotech stocks are rarely seen as effective dividend stocks. Although drugs are also relatively non-cyclical these stocks are often impacted by ever-changing regulatory environment and the strength ofRead More...
InvestorPlace•6 days agoMylan NV Could Be Closer to a Breakout Than Most Traders Realize
If it seems like Mylan NV (NASDAQ:MYL) has gotten far more media attention of late than it usually does — almost all of it bullish — you’re not crazy. The recent investor-day event helped the company toot its own horn to be sure, still, MYL stock has been strangely stuck in neutral in recent days. It’s a curious situation that defies the news Mylan has been dishing out that’s been turning some heads.
Market Realist•7 days agoGilead Sciences Expects Decline in Earnings in Fiscal 2018
Gilead Sciences (GILD) expects to witness non-GAAP gross product margin in the range of 85% to 87% in fiscal 2018. The company has also projected non-GAAP research and development (or R&D) and selling, general, and administrative (or SG&A) expenses in the range of $3.4 billion to $3.6 billion, respectively. The company has also projected a diluted earnings per share (or EPS) impact of $0.41 to $1.51, attributable to stock-based compensation paid for acquisitions and other related expenses.
- Moody's•7 days ago
Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising
The global pharmaceutical industry will see annual earnings growth of 1%-2% over the next 12 to 18 months, supporting a stable outlook on the sector, Moody's Investors Service says in its just-released report. The rating agency's stable outlook and modest EBITDA growth reflect solid underlying fundamentals, including rising utilization of prescription drugs, expansion in emerging markets and positive pricing trends in the US in many therapeutic areas. Among the diverse group of pharmaceutical companies rated by Moody's, those focusing on cancer drugs will see the highest EBITDA growth of more than 10%, while companies with a strong portfolio of products treating rare diseases will see solid growth in the 6%-10% range.
- Zacks•7 days ago
Roche Hemophilia Drug Gets Breakthrough Therapy Designation
The FDA grants Breakthrough Therapy Designation to Roche's (RHHBY) Hemlibra for treatment of people with hemophilia A without factor VIII inhibitors.
Market Realist•7 days agoGilead Sciences May Witness Significant Drop in Revenues in 2018
Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.8 billion to $0. ...
Market Realist•7 days agoWhat Analysts Recommend for Gilead Sciences in April 2018
In 4Q17, Gilead Sciences (GILD) reported revenues close to $5.9 billion, which is a year-over-year (or YoY) drop of around 19%. Gilead Sciences reported net product sales close to $5.8 billion in 4Q17, which is a YoY decline of 19% and a quarter-over-quarter drop close to 9%. The company also reported net product sales close to $25.7 billion for fiscal 2017, which is a YoY decline of around 14%.
Market Realist•8 days agoAnalysts’ Recommendations for AbbVie in April 2018
In April 2018, the FDA notified AbbVie (ABBV) and Neurocrine Biosciences that it would need more time to review liver function test data provided by AbbVie with its new drug application for Elagolix for the management of endometriosis-associated pain, extending its Prescription Drug User Fee Act goal date by three months to 3Q18. In 4Q17, the FDA granted Elagolix priority review. In clinical trials, Elagolix was evaluated for safety and efficacy in ~1,700 women with moderate-to-severe endometriosis-related pain.
